Cargando…

Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods

Baloxavir, a new antiviral drug targeting cap-dependent endonuclease activity of polymerase acidic (PA) protein of influenza viruses, is now approved in multiple countries. Several substitutions at isoleucine 38 in PA protein (e.g., PA-I38T) have been associated with decreased baloxavir susceptibili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Mira C., Mishin, Vasiliy P., De La Cruz, Juan A., Chesnokov, Anton, Nguyen, Ha T., Wilson, Malania M., Barnes, John, Kondor, Rebecca J.G., Wentworth, David E., Gubareva, Larisa V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426223/ https://www.ncbi.nlm.nih.gov/pubmed/32798601 http://dx.doi.org/10.1016/j.antiviral.2020.104906

Ejemplares similares

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
por: Mishin, Vasiliy P., et al.
Publicado: (2019)

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons
por: Gubareva, Larisa V, et al.
Publicado: (2019)

An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance
por: Patel, Mira C., et al.
Publicado: (2022)

Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir
por: Patel, Mira C., et al.
Publicado: (2021)

Cluster of Oseltamivir-Resistant and Hemagglutinin Antigenically Drifted Influenza A(H1N1)pdm09 Viruses, Texas, USA, January 2020
por: Mohan, Teena, et al.
Publicado: (2021)

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011–2018
por: Jorquera, Patricia A., et al.
Publicado: (2019)

An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality
por: Marjuki, Henju, et al.
Publicado: (2014)

Detection of oseltamivir‐resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test
por: Hodges, Erin N., et al.
Publicado: (2019)

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020
por: Govorkova, Elena A., et al.
Publicado: (2022)

Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022
por: Nguyen, Ha T., et al.
Publicado: (2023)

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART
por: Gubareva, Larisa V, et al.
Publicado: (2017)

Antiviral Drug–Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016
por: Baranovich, Tatiana, et al.
Publicado: (2017)

Modeling mitigation of influenza epidemics by baloxavir
por: Du, Zhanwei, et al.
Publicado: (2020)

Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective
por: Okomo-Adhiambo, Margaret, et al.
Publicado: (2010)

A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions
por: Koszalka, Paulina, et al.
Publicado: (2020)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

Correction: Okomo-Adhiambo, M. et al. Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. Viruses 2010, 2, 2269–2289
por: Okomo-Adhiambo, Margaret, et al.
Publicado: (2011)

Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Isolated from Poultry, Vietnam, 2009–2011
por: Nguyen, Ha T., et al.
Publicado: (2013)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice
por: Yoshii, Naoko, et al.
Publicado: (2020)

97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
por: Checkmahomed, Liva, et al.
Publicado: (2019)

2645. Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A
por: Shah, Sunish, et al.
Publicado: (2019)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals
por: Liu, Yanmei, et al.
Publicado: (2022)

A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes
por: Clementi, Nicola, et al.
Publicado: (2011)

Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
por: Kamioka, Yasuhiro, et al.
Publicado: (2020)

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins
por: Marjuki, Henju, et al.
Publicado: (2016)

1350. Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
por: Checkmahomed, Liva, et al.
Publicado: (2020)

Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
por: Portsmouth, Simon, et al.
Publicado: (2020)

Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid
por: Saim-Mamoun, Amel, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications
por: Koshimichi, Hiroki, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

648. Baloxavir Resistance: qPCR Detection of Antiviral Resistance Markers in Influenza A Virus
por: Tyler, Aaron J, et al.
Publicado: (2019)

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
por: Fukao, Keita, et al.
Publicado: (2023)

922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
por: Hansen, Svenn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rueimnmep6j34edgttmlrd8qa0